Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm
Ferdinando D'Amico1,2, Laurent Peyrin-Biroulet3, Silvio Danese2
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Journal of Crohn'S & Colitis
|May 13, 2022
Summary
Ustekinumab effectively treats moderate to severe Crohn's disease (CD) in biologic-naive and experienced patients. This review details its efficacy and safety, aiming to guide optimal ustekinumab management strategies for Crohn's disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Moderate to severe Crohn's disease (CD) presents significant treatment challenges.
- Current therapies include steroids, immunosuppressants, anti-TNFα agents, vedolizumab, and ustekinumab.
- Ustekinumab, a monoclonal antibody targeting IL-12/IL-23, is approved for CD management.
Purpose of the Study:
- To review recent efficacy and safety data for ustekinumab in moderate to severe CD.
- To define optimal management strategies and therapeutic algorithms for ustekinumab in CD patients.
- To consolidate current knowledge on ustekinumab for gastroenterologists and immunologists.
Main Methods:
- Systematic literature review of randomized clinical trials and real-world studies.
- Analysis of efficacy endpoints (clinical remission, endoscopic response) and safety profiles.
- Synthesis of data to inform clinical decision-making for ustekinumab therapy.
Main Results:
- Ustekinumab demonstrates significant efficacy and a favorable safety profile in diverse CD patient populations.
- Studies confirm its effectiveness in both biologic-naive and previously treated patients.
- Real-world data support the findings from clinical trials, highlighting sustained response rates.
Conclusions:
- Ustekinumab is a valuable therapeutic option for moderate to severe Crohn's disease.
- Further research and consensus are needed to establish definitive treatment algorithms.
- Optimizing ustekinumab use can improve outcomes for patients with Crohn's disease.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
8.4K
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
7.7K
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:29Inflammatory Bowel Disease IV: Pharmacological Management
208
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
208
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
219
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
219
01:30Inflammatory Bowel Disease II: Crohn's Disease
413
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
413
01:29Drugs for Treatment of Ulcerative Colitis in IBD
251
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
251